“Cutaneous Safety Profile of Nemolizumab in Moderate‑to‑Severe Atopic Dermatitis and Prurigo Nodularis: Pooled Analysis of Phase 3 Trials (ARCADIA 1&2 and OLYMPIA 1&2) Nodularis: Pooled Analysis of Phase 3 Trials (ARCADIA 1&2 and OLYMPIA 1&2)” (2026) SKIN The Journal of Cutaneous Medicine, 10(2), p. s748. doi:10.25251/yghmqq47.